Table 3.

Minimum health outcomes for treatment continuation.

Disease Activity (Composite Index)	HRQOL (PROM)	Rate of Agreement on Treatment Continuation, n = 97^‡
Disease Activity (Composite Index)	Profile A^†, %	Profile B^†, %	Profile C^†, %
Remission	Optimal	100^*	100^*	100^*
Remission	Suboptimal with CII	99.0^*	99.0^*	99.0^*
Remission	Suboptimal without CII	61.9	78.4^*	88.7^*
Low activity	Optimal	95.9^*	97.9^*	97.9^*
Low activity	Suboptimal with CII	89.7^*	95.9^*	97.9^*
Low activity	Suboptimal without CII	25.8	47.4	75.3^*
Moderate/high activity with CII	Optimal	61.9	67.0	82.5^*
Moderate/high activity with CII	Suboptimal with CII	40.2	51.5	72.2
Moderate/high activity with CII	Suboptimal without CII	7.2	10.3	29.9
Moderate/high activity without CII	Optimal	10.3	15.5	27.8
Moderate/high activity without CII	Suboptimal with CII	6.2	8.2	10.3
Moderate/high activity without CII	Suboptimal without CII	3.1	3.1	2.1

↵‡ Nine participants failed in the test scenario and their responses were subtracted from the analysis.
↵† Patient profile A, naive to biological treatment; patient profile B, without structural damage, and functional disability and/or mild-moderate psoriasis, and failure to 1 biological treatment; patient profile C, with structural damage, serious sequelae, and failure to several biological treatments.
↵* Consensus reached (≥ 75%). HRQOL: health-related quality of life; PROM: patient-reported outcome measures; CII: clinically important improvement.